ReviewTransfusion2022
Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic.
Review in Transfusion, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Article
- Associations of blood donor and product characteristics with platelet transfusion outcomes.Blood advances · 2026Article
- A blood safety perspective on emerging arboviral infections in the United Kingdom.Transfusion medicine (Oxford, England) · 2026Review
- Article
- The evolving landscape of platelet therapy: risks, innovations, and clinical judgment.Annals of hematology · 2026Review
- Optimized pathogen reduction of double-dose platelets pooled from seven buffy coats using the TACSI® system.Vox sanguinis · 2025Article
- Pathogen reduction diminishes the protective effects of platelets on endothelial barrier permeability in vitro.Blood vessels, thrombosis & hemostasis · 2025Article
- Ultrastructure of human platelet concentrates after treatment with pathogen reduction technologies for prolonged storage.Frontiers in medicine · 2025Article
- 405 nm violet-blue light inactivates hepatitis C cell culture virus (HCVcc) in ex vivo human platelet concentrates and plasma.Scientific reports · 2024Article
- Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients.Blood advances · 2024Article
- Platelet Pathogen Reduction Technology-Should We Stay or Should We Go…?Journal of clinical medicine · 2024Article
- The effects of pathogen reduction technology on apheresis platelet concentrates stored in PAS.Blood transfusion = Trasfusione del sangue · 2024Article
- Delayed cold-stored vs. room temperature stored platelet transfusions in bleeding adult cardiac surgery patients-a randomized multicentre pilot study (PLTS-1).Pilot and feasibility studies · 2024Article
- Microbial reduction of prebagged human plasma using 405 nm light and its effects on coagulation factors.AMB Express · 2024Article
- Spectroscopic view on the interaction between the psoralen derivative amotosalen and DNA.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024Article
- Evaluation of bacterial safety approaches of platelet blood concentrates: bacterial screening and pathogen reduction.Frontiers in medicine · 2024Review
- Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery.Journal of biomedical science · 2023Review
- Visible 405 nm Violet-Blue Light Successfully Inactivates HIV-1 in Human Plasma.Pathogens (Basel, Switzerland) · 2022Article
- In Vitro Comparative Study of Platelets Treated with Two Pathogen-Inactivation Methods to Extend Shelf Life to 7 Days.Pathogens (Basel, Switzerland) · 2022Article
- Pathogen Reduction for Platelets-A Review of Recent Implementation Strategies.Pathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Standard platelet concentrates (PCs) stored at 22°C have a limited shelf life of 5 days. Because of the storage temperature, bacterial contamination of PCs can result in life-threatening infections in transfused patients. The potential of blood components to cause infections through contaminating pathogens or transmitting blood-borne diseases has always been a concern. The current safety practice to prevent pathogen transmission through blood transfusion starts with a stringent screening of donors and regulated testing of blood samples to ensure that known infections cannot reach transfusion products. Pathogen reduction technologies (PRTs), initially implemented to ensure the safety of plasma products, have been adapted to treat platelet products. In addition to reducing bacterial contamination, PRT applied to PCs can extend their shelf life up to 7 days, alleviating the impact of their shortage, while providing an additional safety layer against emerging blood-borne infectious diseases. While a deleterious action of PRTs in quantitative and qualitative aspects of plasma is accepted, the impact of PRTs on the quality, function, and clinical efficacy of PCs has been under constant examination. The potential of PRTs to prevent the possibility of new emerging diseases to reach cellular blood components has been considered more hypothetical than real. In 2019, a coronavirus-related disease (COVID-19) became a pandemic. This episode should help when reconsidering the possibility of future blood transmissible threats. The following text intends to evaluate the impact of different PRTs on the quality, function, and clinical effectiveness of platelets within the perspective of a developing pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.